HERG Screening Market Overview
hERG screening has played an important role as a component of cardiac safety pharmacology for the past many years. Over the years, major market players in the hERG screening market are focusing on various growth strategies such as product launches, product advancements, and expansions to cater to the growing needs. For instance, Eurofins Scientific announced the acquisition of DiscoverX, a leader in drug discovery products and services across all stages of discovery from target identification and led discovery to preclinical and beyond.The increasing novel drug approvals and the growing prevalence of heart diseases are driving the HERG Screening Market .However, the high cost of hERG screening products is expected to hamper the growth of this market during the forecast period. Nevertheless, untapped markets are likely to set a lucrative opportunity for the growth of this market in the near future.
hERG screening is primarily used for the drug discovery process. The increasing number of product launches is anticipated to boost the demand for hERG screening in the coming years. According to the annual report published by the Center for Drug Evaluation and Research (CDER), an estimated 25 drugs received novel drugs approval for marketing in 2016, whereas 59 in 2018. The increasing number of novel drugs approvals is expected to support the drugs discovery process that helps the HERG screening market to grow.
HERG Screening Market Segmentation
Global hERG Screening Market is segmented into Type, i.e., gene KCNH2 and mutant KCNH2. KCNH2 gene that provides guidelines for producing potassium channels and held the largest market share in the hERG screening market. The global hERG screening market is segmented based on ion channel, further bifurcated into voltage-gated ion channel, ligand-gated ion channel, and others. Voltage-gated ion channel held the largest share in the hERG screening market, whereas ion-gated channel is the fastest-growing segment. The application segment is divided into antiarrhythmic drugs, antipsychotics, antibiotics, and others. The antiarrhythmic drug application segment is projected to account for a considerable market share.
The HERG screening global market, on the basis of type, has been segmented into gene KCNH2 and mutant KCNH2. KCNH2 gene that provides guidelines for producing potassium channels, where this channel transports positively charged atoms of potassium out of the cells and plays a key role in generating & transmitting electrical signals. The mutation in KCNH2 causes cardiac arrhythmia. Similarly, long QT syndrome is caused by mutations in KCNH2, where an estimated 1 in 5,000–10,000 people suffered from long QT syndrome across the globe.
The HERG screening market is segmented, based on the ion channel, into voltage-gated ion channel, ligand-gated ion channel, and others. Voltage gated ion channel held the largest share of the HERG screening global market, whereas ion gated channel is the fastest-growing segment. The major factors attributed to the market growth of this segment are screening of drugs for (Human Ether-a-go-go related gene) hERG in early stages of drug discovery and development, robust growth in the pharmaceutical companies for hERG screening of lead compounds, and challenges in developing products useful for pharmaceutical and biotechnology applications.
HERG Screening Market Regional Analysis
The global hERG screening market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas has been segmented into North America and Latin America, with the North America market further divided into the US and Canada. The Americas held the largest share of 37.3% of the hERG screening market in 2019. This share can be attributed to technological development and the high prevalence of cardiac disease in the region.
The Europe hERG screening market has been segmented into Western Europe and Eastern Europe. The Western Europe hERG screening market has further been classified into Germany, France, the UK, Italy, Spain, and the Rest of Western Europe. The major players of these countries are involved in new launches and acquisitions in the hERG screening market. The hERG screening market in Asia-Pacific has been segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia-Pacific. The market growth in these countries is attributed to the large pool of patients suffering from cardiac disorders and the need for drug formulation and development to cure these disorders. The Middle East & Africa hERG screening market has been divided into the Middle East and Africa.
HERG Screening Market Players
- Charles River Laboratories
- Eurofins Scientific
- Merck KGaA
- Cyprotex Limited
This market are FDA approvals, joint ventures, acquisitions, expansions, and collaborations
Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/herg-screening-market-10386
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071